Tizanidine Hydrochloride Capsule
Product Images NDC 68788-8776

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 68788-8776). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

A Yellow Rectangular Box With Black Textdescription Automatically Generated (Tizanidine Hydrochloride Capsules 4mg 150 Count)

A Yellow Rectangular Box With Black Textdescription Automatically Generated (Tizanidine Hydrochloride Capsules 4mg 150 Count)
The packaging label for Tizanidine Hydrochloride Capsules 4 mg, a generic for Zanaflex, from Preferred Pharmaceuticals Inc. The label states each capsule contains 4.58 mg tizanidine hydrochloride USP equivalent to 4 mg tizanidine base. The capsules are blue and white, imprinted with UpArrowhead 044. The label includes storage instructions, a warning about drowsiness, and space for lot number, batch number, expiration date, and insurance information. Manufacturer noted as Rubicon Research Private Limited.*
FDA Label Image

Figure 1 (Tizanidine Hydrochloride Capsules Figure 1)

Figure 1 (Tizanidine Hydrochloride Capsules Figure 1)
A line graph depicting plasma tizanidine concentration (ng/mL) over time (hours) after dosing. It compares the concentration profiles of 4 mg tizanidine tablets and capsules taken with and without food, showing how concentration changes during the 24-hour period post-dose.*
FDA Label Image

Figure 2 (Tizanidine Hydrochloride Capsules Figure 2)

Figure 2 (Tizanidine Hydrochloride Capsules Figure 2)
A line graph showing the improvement in Ashworth Score over six hours post-dose, comparing three groups: 16 mg tizanidine, 8 mg tizanidine, and placebo. The graph illustrates higher improvement scores with 16 mg and 8 mg tizanidine than placebo, with peak improvement occurring around 2 hours post-dose.*
FDA Label Image

Figure 3 (Tizanidine Hydrochloride Capsules Figure 3)

Figure 3 (Tizanidine Hydrochloride Capsules Figure 3)
A line graph showing improvement in Ashworth Score over three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation Carried Forward). The graph compares tizanidine (mean dose 28.8 mg) with placebo, depicting greater score improvement for tizanidine across all points with error bars.*
FDA Label Image

Chemical Structural Formula (Tizanidine Hydrochloride Capsules Structure)

Chemical Structural Formula (Tizanidine Hydrochloride Capsules Structure)
Chemical structure of tizanidine hydrochloride showing its molecular framework, including a chlorinated aromatic ring and a thiazole ring attached to an imidazoline moiety with an HCl group.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.